Sequential Therapy of Linezolid and Contezolid to Treat Vancomycin-Resistant Enterococcus faecium Pneumonia in a Centenarian Patient: Case Report

References

• Fiore E, Van Tyne D, Gilmore MS. Pathogenicity of enterococci. Microbiol Spectr. 2019;7(4):1. doi:10.1128/microbiolspec.GPP3-0053-2018
   Web of Science ®Google Scholar
• Li F, Wang Y, Sun L, Wang X. Vancomycin-resistant Enterococcus faecium pneumonia in a uremic patient on hemodialysis: a case report and review of the literature. BMC Infect Dis. 2020;20(1):167. doi:10.1186/s12879-020-4892-4
   PubMed Web of Science ®Google Scholar
• Grupper M, Kravtsov A, Potasman I. Enterococcal-associated lower respiratory tract infections: a case report and literature review. Infection. 2009;37(1):60–64. doi:10.1007/s15010-007-7123-7
   PubMed Web of Science ®Google Scholar
• Kimura Y, Kobayashi I. 溺水後にEnterococcus faeciumによる肺炎をきたした1例[A case of pneumonia due to Enterococcus faecium after near drowing]. Kansenshogaku Zasshi. 2011;85(4):380–383. Japanese. doi:10.11150/kansenshogakuzasshi.85.380
   PubMedGoogle Scholar
• Zhou X, Willems RJL, Friedrich AW, Rossen JWA, Bathoorn E. Enterococcus faecium: from microbiological insights to practical recommendations for infection control and diagnostics. Antimicrob Resist Infect Control. 2020;9(1):130. doi:10.1186/s13756-020-00770-1
   PubMed Web of Science ®Google Scholar
• Bi LQ, Zhou J, Huang M, Zhou SM. Efficacy of linezolid on gram-positive bacterial infection in elderly patients and the risk factors associated with thrombocytopenia. Pak J Med Sci. 2013;29(3):837–842. doi:10.12669/pjms.293.2925
   PubMed Web of Science ®Google Scholar
• Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect. 2009;59(Suppl 1):S59–74. doi:10.1016/s0163-4453(09)60009-8
   PubMed Web of Science ®Google Scholar
• Hoy SM. Contezolid: first approval. Drugs. 2021;81(13):1587–1591. doi:10.1007/s40265-021-01576-0
   PubMed Web of Science ®Google Scholar
• MicuRx Pharmaceuticals, Inc. MicuRx reports positive top-line results of a China Phase 3 clinical trial for novel antibiotic contezolid in complicated skin and soft tissue infections. MicuRx Pharmaceuticals; 2019.
   Google Scholar
• Agudelo Higuita NI, Huycke MM. Enterococcal disease, epidemiology, and implications for treatment. In: Gilmore MS, Clewell DB, Ike Y, Shankar N, editors. Enterococci: From Commensals to Leading Causes of Drug Resistant Infection. Massachusetts Eye and Ear Infirmary; 2014.
   Google Scholar
• Alduhaidhawi AHM, AlHuchaimi SN, Al-Mayah TA, et al. Prevalence of CRISPR-cas systems and their possible association with antibiotic resistance in Enterococcus faecalis and Enterococcus faecium collected from hospital wastewater. Infect Drug Resist. 2022;15:1143–1154. doi:10.2147/idr.S358248
   PubMed Web of Science ®Google Scholar
• Raza T, Ullah SR, Mehmood K, Andleeb S. Vancomycin resistant Enterococci: a brief review. J Pak Med Assoc. 2018;68(5):768–772.
   PubMed Web of Science ®Google Scholar
• Patterson JE, Sweeney AH, Simms M, et al. An analysis of 110 serious enterococcal infections epidemiology, antibiotic susceptibility, and outcome. Medicine. 1995;74(4):191–200.
   PubMed Web of Science ®Google Scholar
• Levitus M, Rewane A, Perera TB. Vancomycin-resistant enterococci. In: StatPearls. StatPearls Publishing; 2022.
   Google Scholar
• Stagliano DR, Susi A, Adams DJ, Nylund CM; Lt Col. Epidemiology and outcomes of vancomycin-resistant enterococcus infections in the U.S. military health system. Mil Med. 2021;186(Supplement_1):100–107. doi:10.1093/milmed/usaa229
   PubMedGoogle Scholar
• Olawale KO, Fadiora SO, Taiwo SS. Prevalence of hospital-acquired enterococci infections in two primary-care hospitals in Osogbo, southwestern Nigeria. Afr J Infect Dis. 2011;5(2):40–46. doi:10.4314/ajid.v5i2.66513
   PubMedGoogle Scholar
• Savini V, Gherardi G, Astolfi D, et al. Insights into airway infections by enterococci: a review. Recent Pat Antiinfect Drug Discov. 2012;7(1):36–44. doi:10.2174/157489112799829774
   PubMedGoogle Scholar
• Morris JF, Okies JE. Enterococcal lung abscess: medical and surgical therapy. Chest. 1974;65(6):688–691. doi:10.1378/chest.65.6.688
   PubMed Web of Science ®Google Scholar
• Vanschooneveld T, Mindru C, Madariaga MG, Kalil AC, Florescu DF. Enterococcus pneumonia complicated with empyema and lung abscess in an HIV-positive patient. Case report and review of the literature. Int J STD AIDS. 2009;20(9):659–661. doi:10.1258/ijsa.2008.008456
   PubMed Web of Science ®Google Scholar
• Levora J, Teplan V, Viklický O. Enterococcus faecium as a cause of pulmonary abscesses in kidney transplant recipient. Transpl Int. 2007;20(3):297–298. doi:10.1111/j.1432-2277.2006.00403.x
   PubMed Web of Science ®Google Scholar
• Giarratano A, Green SE, Nicolau DP. Review of antimicrobial use and considerations in the elderly population. Clin Interv Aging. 2018;13:657–667. doi:10.2147/cia.S133640
   PubMed Web of Science ®Google Scholar
• Beckett CL, Harbarth S, Huttner B. Special considerations of antibiotic prescription in the geriatric population. Clin Microbiol Infect. 2015;21(1):3–9. doi:10.1016/j.cmi.2014.08.018
   PubMed Web of Science ®Google Scholar
• Nishijo N, Tsuji Y, Matsunaga K, et al. Mechanism underlying linezolid-induced thrombocytopenia in a chronic kidney failure mouse model. J Pharmacol Pharmacother. 2017;8(1):8–13. doi:10.4103/jpp.JPP_167_16
   PubMedGoogle Scholar
• Tajima M, Kato Y, Matsumoto J, et al. Linezolid-induced thrombocytopenia is caused by suppression of platelet production via phosphorylation of myosin light chain 2. Biol Pharm Bull. 2016;39(11):1846–1851. doi:10.1248/bpb.b16-00427
   PubMed Web of Science ®Google Scholar
• Meng J, Zhong D, Li L, et al. Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: the oxidative ring opening of 2,3-Dihydropyridin-4-one catalyzed by non-P450 enzymes. Drug Metab Dispos. 2015;43(5):646–659. doi:10.1124/dmd.114.061747
   PubMed Web of Science ®Google Scholar
• Zhao X, Huang H, Yuan H, Yuan Z, Zhang Y. A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections. J Antimicrob Chemother. 2022;77(6):1762–1769. doi:10.1093/jac/dkac073
   PubMed Web of Science ®Google Scholar
• Wang S, Cai C, Shen Y, et al. In vitro activity of contezolid against methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and strains with linezolid resistance genes from China. Front Microbiol. 2021;12:729900. doi:10.3389/fmicb.2021.729900
   PubMed Web of Science ®Google Scholar
• Kang Y, Ge C, Zhang H, Liu S, Guo H, Cui J. Compassionate use of contezolid for the treatment of tuberculous pleurisy in a patient with a leadless pacemaker. Infect Drug Resist. 2022;15:4467–4470. doi:10.2147/idr.S373082
   PubMed Web of Science ®Google Scholar
• Shoen C, DeStefano M, Hafkin B, Cynamon M. In vitro and in vivo activities of contezolid (MRX-I) against mycobacterium tuberculosis. Antimicrob Agents Chemother. 2018;62(8):1. doi:10.1128/aac.00493-18
   Web of Science ®Google Scholar